Angiomax Gains Second Label Expansion For 2005; FDA Requests Patient Registry
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Medicines Company's anticoagulant Angiomax cleared FDA Nov. 30 for use in patients undergoing percutaneous coronary intervention (PCI) who either have or are at risk for heparin-related complications